Methylation of SRD5A2 promoter predicts a better outcome for castration-resistant prostate cancer patients undergoing androgen deprivation therapy
Wang, Z., T. Deng, X. Long, X. Lin, S. Wu, H. Wang, R. Ge, et al. 2020. Methylation of SRD5A2 Promoter Predicts a Better Outcome for Castration-Resistant Prostate Cancer Patients Undergoing Androgen Deprivation Therapy.